Liquidia Co. (NASDAQ:LQDA) Insider Jason Adair Sells 1,856 Shares

Liquidia Co. (NASDAQ:LQDA) insider Jason Adair sold 1,856 shares of Liquidia stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $25,185.92. Following the completion of the transaction, the insider now directly owns 184,304 shares of the company’s stock, valued at $2,501,005.28. This represents a 1.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jason Adair also recently made the following trade(s):

• On Monday, January 27th, Jason Adair sold 445 shares of Liquidia stock. The stock was sold at an average price of $14.20, for a total transaction of $6,319.00.

Liquidia Stock Performance

LQDA opened at $13.72 on Friday. Liquidia Co. has a twelve month low of $8.26 and a twelve month high of $16.81. The firm has a market cap of $1.17 billion, a PE ratio of -8.42 and a beta of 0.23. The firm’s fifty day moving average is $14.70 and its two-hundred day moving average is $12.76.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The business had revenue of $2.92 million for the quarter, compared to analyst estimates of $4.60 million. Equities analysts forecast that Liquidia Co. will post -1.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on LQDA shares. Scotiabank reaffirmed an “outperform” rating on shares of Liquidia in a report on Thursday, March 20th. Wells Fargo & Company began coverage on Liquidia in a report on Friday, December 20th. They set an “overweight” rating and a $20.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $29.00 price target on shares of Liquidia in a research report on Thursday, March 20th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 target price on shares of Liquidia in a report on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Liquidia currently has an average rating of “Buy” and an average price target of $26.63.

Hedge Funds Weigh In On Liquidia

Several institutional investors have recently modified their holdings of LQDA. GAMMA Investing LLC increased its stake in Liquidia by 65.6% during the 1st quarter. GAMMA Investing LLC now owns 2,961 shares of the company’s stock worth $44,000 after purchasing an additional 1,173 shares in the last quarter. Steward Partners Investment Advisory LLC bought a new stake in shares of Liquidia during the fourth quarter worth $59,000. Summit Investment Advisors Inc. raised its holdings in shares of Liquidia by 35.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock worth $78,000 after acquiring an additional 1,719 shares during the period. D. E. Shaw & Co. Inc. bought a new stake in Liquidia in the 4th quarter valued at $142,000. Finally, EntryPoint Capital LLC acquired a new position in Liquidia in the 4th quarter worth $154,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).